Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-10 of 10 for your search:
Drug:
iobenguane I 131
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma
Phase:
Phase IV, Phase III
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
GPOH-NB2004
, EU-20661, NCT00410631
2.
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MIP-IB12
, NCT00458952
3.
131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-Risk Neuroblastoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 14
Sponsor:
Other
Protocol IDs:
87-01-36-6853
, NCT00798148
4.
Phase II Pilot Study of Targeted Radiotherapy Using Iodine I 131 Metaiodobenzylguanidine in Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Chromaffin Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 1
Sponsor:
Other
Protocol IDs:
MSKCC-04148
, NCT00107289
5.
Phase II Study of Iodine I 131 Metaiodobenzylguanidine and Combination Chemotherapy Comprising Carboplatin, Etoposide, and Melphalan Followed By Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation and Radiotherapy in Patients With Relapsed or Refractory Neuroblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
1 to 29
Sponsor:
NCI
Protocol IDs:
NANT-2001-02
, NCT00253435
6.
A Study Evaluating Ultratrace Iobenguane I 131(MIBG)in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase:
Phase II
Type:
Treatment
Status:
Approved-not yet active
Age:
12 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MIP-IB12B
, NCT00874614
7.
Phase I Study of Irinotecan Hydrochloride, Vincristine, and Iodine I 131 Metaiodobenzylguanidine in Young Patients With Resistant or Relapsed High-Risk Neuroblastoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
1 to 30
Sponsor:
NCI
Protocol IDs:
NANT-2004-06
, NANT N2004-06, NANT-N04-06, NANT-Draximage-2007-01, NCT00509353
8.
Diagnosis of Pheochromocytoma
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Diagnostic
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
000093
, 00-CH-0093, NCT00004847
9.
Randomized Study of Standard Induction Chemotherapy Versus Topotecan Hydrochloride-Containing Induction Chemotherapy Followed by Myeloablative Autologous Stem Cell Transplantation and Consolidation Therapy With Isotretinoin in Pediatric Patients With High-Risk Neuroblastoma
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
6 months to 21
Sponsor:
Other
Protocol IDs:
GPOH-NB2004-HR
, NB2004-HR, UNI-KOELN-161, NCT00526318
10.
Haploidentical Stem Cell Transplantation in Neuroblastoma
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
6 months to 21 years
Sponsor:
Other
Protocol IDs:
385/2005
, NCT00790413
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute